Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study

Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study

BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) entails low quality of life for patients and massive societal costs. There is an urgent need for elucidation of disease mechanisms and for rational treatment. Our working hypothesis is that ME/CFS in a subgroup of patients is asso...

Full description

Saved in:
Bibliographic Details
Main Authors: Øystein Fluge, Ingrid Gurvin Rekeland, Kari Sørland, Kine Alme, Kristin Risa, Ove Bruland, Karl Johan Tronstad, Olav Mella
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Medicine
Subjects:
ME/CFS clinical trial
daratumumab
autoantibodies
plasma cell
feasibility
pathomechanism
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1607353/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2025.1607353/full

Similar Items